Forging a link between oncogenic signaling and immunosuppression in melanoma

Jahan S. Khalili; Patrick Hwu; Gregory Lizée

doi:10.4161/onci.22745

Forging a link between oncogenic signaling and immunosuppression in melanoma

Jahan S. Khalili, Patrick Hwu, Gregory Lizée

Melanoma Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

7 Scopus citations

Abstract

Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAFV600E with vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These results suggest that inhibitors of the MAPK pathway in combination with T cell-based immunotherapies may induce long-lasting and durable responses.

Original language	English (US)
Article number	e22745
Journal	OncoImmunology
Volume	2
Issue number	2
DOIs	https://doi.org/10.4161/onci.22745
State	Published - Feb 2013

Keywords

BRAF
COX-2
Cytotoxic T cells
Immune suppression
Interleukin-1
PD-1 ligands
Tumor-associated fibroblasts

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/onci.22745

Cite this

@article{41e4768c60e54194a1822f0157499883,

title = "Forging a link between oncogenic signaling and immunosuppression in melanoma",

abstract = "Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAFV600E with vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These results suggest that inhibitors of the MAPK pathway in combination with T cell-based immunotherapies may induce long-lasting and durable responses.",

keywords = "BRAF, COX-2, Cytotoxic T cells, Immune suppression, Interleukin-1, PD-1 ligands, Tumor-associated fibroblasts",

author = "Khalili, {Jahan S.} and Patrick Hwu and Gregory Liz{\'e}e",

year = "2013",

month = feb,

doi = "10.4161/onci.22745",

language = "English (US)",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "2",

}

TY - JOUR

T1 - Forging a link between oncogenic signaling and immunosuppression in melanoma

AU - Khalili, Jahan S.

AU - Hwu, Patrick

AU - Lizée, Gregory

PY - 2013/2

Y1 - 2013/2

N2 - Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAFV600E with vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These results suggest that inhibitors of the MAPK pathway in combination with T cell-based immunotherapies may induce long-lasting and durable responses.

AB - Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAFV600E with vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These results suggest that inhibitors of the MAPK pathway in combination with T cell-based immunotherapies may induce long-lasting and durable responses.

KW - BRAF

KW - COX-2

KW - Cytotoxic T cells

KW - Immune suppression

KW - Interleukin-1

KW - PD-1 ligands

KW - Tumor-associated fibroblasts

UR - http://www.scopus.com/inward/record.url?scp=84886943264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886943264&partnerID=8YFLogxK

U2 - 10.4161/onci.22745

DO - 10.4161/onci.22745

M3 - Comment/debate

C2 - 23525189

AN - SCOPUS:84886943264

SN - 2162-4011

VL - 2

JO - OncoImmunology

JF - OncoImmunology

IS - 2

M1 - e22745

ER -

Forging a link between oncogenic signaling and immunosuppression in melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this